Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19178837 | Salts of Obicetrapib and Processes for their Manufacture and Intermediates Thereof | April 2025 | August 2025 | Allow | 4 | 0 | 0 | Yes | No |
| 18637425 | Salts of Obicetrapib and Processes for their Manufacture and Intermediates Thereof | April 2024 | May 2025 | Allow | 13 | 0 | 0 | Yes | No |
| 18631374 | PYRIMIDO[1',6':1,5]PYRAZOLO[4,3-C][2,7]NAPHTHYRIDINES AS CK2 INHIBITORS | April 2024 | December 2024 | Allow | 8 | 1 | 1 | No | No |
| 18431898 | 4-CHLORO-N'-(2-(5-(4-CHLOROPHENYL)-1,3,4-OXADIAZOL-2-YLTHIO)ACETOXY)BENZIMIDAMIDE AS AN ANTIMICROBIAL COMPOUND | February 2024 | April 2024 | Allow | 3 | 0 | 0 | No | No |
| 18428797 | 4-CHLORO-N'-(2-(5-(4-CHLOROPHENYL)-1,3,4-OXADIAZOL-2-YLTHIO)ACETOXY)BENZIMIDAMIDE AS AN ANTIMICROBIAL COMPOUND | January 2024 | April 2024 | Allow | 2 | 0 | 0 | Yes | No |
| 18414019 | SOLID STATE FORMS OF (S)-2-(((S)-6,8-DIFLUORO-1,2,3,4-TETRAHYDRONAPHTHALEN-2-YL)AMINO)-N-(1-(2-METHYL-1-(NEOPENTYLAMINO)PROPAN-2-YL)-1H-IMIDAZOL-4-YL)PENTANAMIDE AND USES THEREOF | January 2024 | August 2024 | Allow | 7 | 1 | 0 | Yes | No |
| 18381078 | 4-(5-(3-FLUOROPHENYL)-4-PHENYL-4H-1,2,4-TRIAZOL-3-YLTHIO)BUTANOIC ACID AS AN ANTIMICROBIAL COMPOUND | October 2023 | February 2024 | Allow | 4 | 0 | 1 | Yes | No |
| 18486898 | 4-CHLORO-N'-(2-(5-(4-CHLOROPHENYL)-1,3,4-OXADIAZOL-2-YLTHIO)ACETOXY)BENZIMIDAMIDE AS AN ANTIMICROBIAL COMPOUND | October 2023 | April 2024 | Allow | 6 | 1 | 1 | Yes | No |
| 18478718 | AMIDE DERIVATIVES OF N-UREA SUBSTITUTED AMINO ACIDS AS FORMYL PEPTIDERECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS | September 2023 | January 2026 | Abandon | 27 | 0 | 1 | No | No |
| 18243318 | HIGH PURITY TIN COMPOUNDS CONTAINING UNSATURATED SUBSTITUENT AND METHOD FOR PREPARATION THEREOF | September 2023 | August 2025 | Abandon | 23 | 1 | 1 | No | No |
| 18361545 | SOLID STATE FORMS OF (S)-2-(((S)-6,8-DIFLUORO-1,2,3,4-TETRAHYDRONAPHTHALEN-2-YL)AMINO)-N-(1-(2-METHYL-1-(NEOPENTYLAMINO)PROPAN-2-YL)-1H-IMIDAZOL-4-YL)PENTANAMIDE AND USES THEREOF | July 2023 | November 2023 | Allow | 3 | 1 | 0 | No | No |
| 18361472 | SOLID STATE FORMS OF (S)-2-(((S)-6,8-DIFLUORO-1,2,3,4-TETRAHYDRONAPHTHALEN-2-YL)AMINO)-N-(1-(2-METHYL-1-(NEOPENTYLAMINO)PROPAN-2-YL)-1H-IMIDAZOL-4-YL)PENTANAMIDE AND USES THEREOF | July 2023 | December 2023 | Allow | 4 | 0 | 0 | Yes | No |
| 18352955 | METHOD FOR INHIBITING OR DISRUPTING BIOFILM FORMATION, OR REDUCING BIOFILM | July 2023 | April 2025 | Allow | 22 | 0 | 0 | Yes | No |
| 18337575 | Coordination Complex and Electronic Device Comprising the Same | June 2023 | September 2025 | Allow | 27 | 1 | 0 | Yes | No |
| 18329479 | MACROCYCLIC COMPOUNDS AND COMPOSITIONS, AND METHODS OF PREPARING AND USING THE SAME | June 2023 | March 2024 | Allow | 10 | 1 | 1 | No | No |
| 18132530 | Use Of Berbamine Dihydrochloride In Preparation Of Ebola Virus Inhibitor | April 2023 | April 2025 | Allow | 24 | 0 | 0 | Yes | No |
| 18117358 | VITAMIN D3 DERIVATIVES AND PHARMACEUTICAL USE THEREOF | March 2023 | September 2025 | Abandon | 31 | 0 | 1 | No | No |
| 18175841 | CHEMICAL SYNTHESIS OF CLOPIDOGREL ACTIVE METABOLITES AND DISULFIDE CONJUGATE PRODRUGS | February 2023 | December 2025 | Abandon | 33 | 0 | 1 | No | No |
| 18173037 | HIGH EFFICIENT SEX PHEROMONE LURES FOR ECTROPIS OBLIQUE AND ECTROPIS GRISESCENS | February 2023 | August 2023 | Allow | 6 | 1 | 0 | No | No |
| 18170884 | SOLID STATE FORMS OF (S)-2-(((S)-6,8-DIFLUORO-1,2,3,4-TETRAHYDRONAPHTHALEN-2-YL)AMINO)-N-(1-(2-METHYL-1-(NEOPENTYLAMINO)PROPAN-2-YL)-1H-IMIDAZOL-4-YL)PENTANAMIDE AND USES THEREOF | February 2023 | October 2023 | Allow | 8 | 1 | 1 | No | No |
| 18108264 | CANNABINOID RECEPTOR MEDIATING COMPOUNDS | February 2023 | January 2024 | Allow | 11 | 1 | 1 | Yes | No |
| 18106543 | SMALL MOLECULE INHIBITORS SELECTIVE FOR POLO-LIKE KINASE PROTEIN | February 2023 | April 2025 | Allow | 26 | 0 | 0 | Yes | No |
| 18160442 | SOLID STATE FORMS OF (S)-2-(((S)-6,8-DIFLUORO-1,2,3,4-TETRAHYDRONAPHTHALEN-2-YL)AMINO)-N-(1-(2-METHYL-1-(NEOPENTYLAMINO)PROPAN-2-YL)-1H-IMIDAZOL-4-YL)PENTANAMIDE AND USES THEREOF | January 2023 | August 2023 | Allow | 6 | 1 | 0 | Yes | No |
| 18157987 | AMIDATED FATTY ACIDS AND DERIVATIVES THEREOF | January 2023 | October 2025 | Allow | 33 | 0 | 1 | Yes | No |
| 18006293 | SELECTION OF CROSSLINKERS AND CONTROL OF MICROSTRUCTURE OF VAPOUR-PHASE CROSSLINKED COMPOSITE MEMBRANES FOR ORGANIC SOLVENT SEPARATION | January 2023 | February 2026 | Abandon | 37 | 0 | 1 | No | No |
| 18157592 | SOLID STATE FORMS OF (S)-2-(((S)-6,8-DIFLUORO-1,2,3,4-TETRAHYDRONAPHTHALEN-2-YL)AMINO)-N-(1-(2-METHYL-1-(NEOPENTYLAMINO)PROPAN-2-YL)-1H-IMIDAZOL-4-YL)PENTANAMIDE AND USES THEREOF | January 2023 | March 2025 | Allow | 26 | 0 | 0 | Yes | No |
| 18057633 | COMPOSITIONS OF SOLID FORMS OF (S)-2-(((S)-6,8-DIFLUORO-1,2,3,4-TETRAHYDRONAPHTHALEN-2-YL)AMINO)-N-(1-(2-METHYL-1-(NEOPENTYLAMINO)PROPAN-2-YL)-1H-IMIDAZOL-4-YL)PENTANAMIDE | November 2022 | November 2023 | Allow | 12 | 2 | 0 | Yes | No |
| 18049073 | SOLID STATE FORMS OF (S)-2-(((S)-6,8-DIFLUORO-1,2,3,4-TETRAHYDRONAPHTHALEN-2-YL)AMINO)-N-(1-(2-METHYL-1-(NEOPENTYLAMINO)PROPAN-2-YL)-1H-IMIDAZOL-4-YL)PENTANAMIDE AND USES THEREOF | October 2022 | August 2023 | Abandon | 10 | 1 | 0 | No | No |
| 17920493 | Synergistic Preservative/Personal Care Composition Containing an Alkylene Glycol Ester | October 2022 | October 2025 | Allow | 36 | 1 | 0 | Yes | No |
| 17996226 | Use of Ovatodiolide against SARS-CoV-2 | October 2022 | July 2025 | Allow | 33 | 0 | 0 | Yes | No |
| 17938590 | COMPOSITIONS AND TREATMENTS WITH NIROGACESTAT | October 2022 | March 2024 | Abandon | 17 | 3 | 0 | No | No |
| 17906505 | PHARMACEUTICAL COMPOSITION COMPRISING TIZOXANIDE AND PHARMACEUTICAL USE THEREOF | September 2022 | May 2025 | Allow | 32 | 0 | 0 | Yes | No |
| 17906221 | FUSED BICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | September 2022 | March 2026 | Abandon | 42 | 0 | 1 | No | No |
| 17908612 | USE OF SUBSTITUTED 1,2,4-OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI | September 2022 | December 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17908617 | APPLICATION OF DIMETHYL BERBAMINE COMPOUND IN INHIBITION OF SARS-COV-2 | September 2022 | December 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17908073 | OXIDE-SUPPORTED COBALT CATALYST CAPABLE OF ACCELERATING REDUCTIVE AMINATION | August 2022 | December 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17802223 | COMBINATION COMPRISING ALPELISIB AND 6-(2,4-DICHLOROPHENYL)-5-[4-[(3S)-1-(3-FLUOROPROPYL)PYRROLIDIN-3-YL]OXYPHENYL]-8,9-DIHYDRO-7H-BENZO[7]ANNULENE-2-CARBOXYLIC ACID | August 2022 | March 2025 | Allow | 31 | 0 | 0 | No | No |
| 17820348 | NOVEL HETEROARYL BUTANOIC ACID DERIVATIVES | August 2022 | April 2025 | Allow | 32 | 0 | 1 | No | No |
| 17760283 | Composition and Method for the Treatment and Prevention of Cardiac, Pulmonary, Dermal, and Renal Fibrosis | August 2022 | February 2026 | Abandon | 43 | 1 | 0 | No | No |
| 17759562 | PESTICIDALLY ACTIVE FUSED BICYCLIC HETEROAROMATIC AMINO COMPOUNDS | July 2022 | December 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17808246 | DYES, DYE-SENSITIZED SOLAR CELLS, AND METHODS OF MAKING AND USING THE SAME | June 2022 | January 2026 | Abandon | 43 | 0 | 1 | No | No |
| 17840952 | TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | June 2022 | August 2023 | Allow | 14 | 2 | 0 | Yes | No |
| 17838061 | FURANIC DIGLYCIDYL ETHERS AND ESTERS AND USE THEREOF | June 2022 | August 2025 | Allow | 38 | 1 | 1 | Yes | No |
| 17835551 | METHOD OF THERAPEUTICALLY TREATING CANCER | June 2022 | July 2025 | Allow | 37 | 1 | 1 | Yes | No |
| 17664134 | MEVALONATE PATHWAY INHIBITOR AS HIGHLY-EFFICIENT VACCINE ADJUVANT | May 2022 | April 2025 | Abandon | 35 | 2 | 1 | Yes | No |
| 17774239 | ERAP1 MODULATORS | May 2022 | March 2025 | Allow | 35 | 0 | 0 | Yes | No |
| 17728623 | METHOD OF MODULATING RIBONUCLEOTIDE REDUCTASE | April 2022 | July 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17755103 | NOVEL HETEROCYCLIC COMPOUNDS | April 2022 | January 2025 | Allow | 33 | 1 | 1 | Yes | No |
| 17639280 | COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES | February 2022 | May 2025 | Allow | 38 | 0 | 0 | Yes | No |
| 17635939 | Safe, Environmentally Friendly and Controllable Method for Preparing Cycloaliphatic Diepoxides | February 2022 | February 2026 | Abandon | 48 | 1 | 1 | No | No |
| 17634505 | SALT AND CRYSTAL FORM OF COMPOUND HAVING AGONISTIC ACTIVITY TO S1P5 RECEPTOR | February 2022 | July 2025 | Allow | 41 | 1 | 1 | Yes | No |
| 17667699 | Diagnosis and Treatment of Vitiligo | February 2022 | January 2023 | Allow | 11 | 1 | 0 | No | No |
| 17632027 | IMIDAZO[2,1-F][1,2,4]TRIAZIN-4-AMINE DERIVATIVES USED AS TLR8 AGONISTS | February 2022 | August 2025 | Allow | 42 | 1 | 0 | No | No |
| 17630532 | METHOD FOR CHLORINATING BLUE ANTHRONE, VIOLANTHRONE OR ISOVIOLANTRONE | January 2022 | December 2023 | Allow | 23 | 1 | 0 | No | No |
| 17628300 | INHIBITORS OF THE STING PATHWAY FOR THE TREATMENT OF HIDRADENITIS SUPPURATIVA | January 2022 | August 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17624870 | CRYSTALLINE LORLATINIB : FUMARIC ACID AND SOLID STATE FORM THEREOF | January 2022 | April 2025 | Allow | 39 | 1 | 1 | Yes | No |
| 17644690 | METHODS FOR CONVERTING CBD, CBDA AND ANALOGS THEREOF INTO DELTA8-THC, DELTA8-THCA AND ANALOGS THEREOF | December 2021 | April 2025 | Allow | 40 | 0 | 0 | Yes | No |
| 17596364 | IMPROVED METHODS FOR CONVERTING CANNABIDIOL INTO DELTA8-TETRAHYDROCANNABINOL | December 2021 | June 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17596355 | METHODS FOR PREPARING CANNABINOIDS BY HETEROGENEOUS-ACID-PROMOTED DOUBLE-BOND MIGRATION | December 2021 | June 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17452970 | CATIONIC PILLARARENE COMPOUNDS AND COMPOSITIONS | October 2021 | September 2023 | Abandon | 23 | 1 | 0 | Yes | No |
| 17605525 | DUAL INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE AND METHODS OF USE THEREOF | October 2021 | December 2024 | Allow | 38 | 2 | 0 | Yes | No |
| 17603846 | MAKING ETHYLENEDIAMINETETRAACETIC ACID | October 2021 | December 2024 | Allow | 38 | 0 | 1 | Yes | No |
| 17497735 | Hydrazinyl-Pyrrolo Compounds and Methods for Producing a Conjugate | October 2021 | September 2024 | Allow | 35 | 2 | 1 | No | No |
| 17495481 | METHOD FOR PRODUCING KAKEROMYCIN AND DERIVATIVES THEREOF | October 2021 | April 2023 | Allow | 19 | 0 | 0 | No | No |
| 17474637 | NITRIC OXIDE DONORS | September 2021 | November 2023 | Abandon | 26 | 0 | 1 | No | No |
| 17470459 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | September 2021 | October 2023 | Abandon | 25 | 0 | 1 | No | No |
| 17470092 | BLUE THERMALLY ACTIVATED DELAYED FLUORESCENT EMITTERS AND HOSTS BASED ON FUNCTIONALIZED IMIDAZOLYL GROUPS | September 2021 | August 2025 | Allow | 47 | 1 | 1 | Yes | No |
| 17468035 | METABOLICALLY STABLE 5-HMF DERIVATIVES FOR THE TREATMENT OF HYPOXIA | September 2021 | February 2022 | Allow | 5 | 1 | 0 | Yes | No |
| 17398016 | 7-Ethyl-10-hydroxycamptothecin derivatives for use in the treatment of cancer | August 2021 | June 2024 | Allow | 35 | 3 | 1 | Yes | No |
| 17429429 | Hemiasterlin Derivative Having Cysteine Residue | August 2021 | January 2025 | Allow | 41 | 1 | 0 | Yes | No |
| 17393834 | METHODS FOR PRODUCING VILOXAZINE SALTS AND NOVEL POLYMORPHS THEREOF | August 2021 | February 2026 | Abandon | 55 | 3 | 1 | Yes | Yes |
| 17392478 | Method for Improving Alkali Resistance and Oxidation Resistance of Benzisothiazole Disperse Dye | August 2021 | June 2024 | Abandon | 34 | 2 | 1 | No | No |
| 17392463 | Method for Improving Alkali Resistance and Oxidation Resistance of Benzothiazole Disperse Dye | August 2021 | August 2024 | Allow | 37 | 3 | 1 | Yes | No |
| 17424413 | BIS(DIAZIRINE) DERIVATIVES AS PHOTO-CROSSLINKER FOR TREATING CORNEAL ECTATIC DISORDERS | July 2021 | February 2025 | Allow | 43 | 1 | 1 | No | No |
| 17376823 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | July 2021 | February 2025 | Allow | 43 | 3 | 1 | Yes | No |
| 17305557 | LIGHT-EMITTING DEVICE AND ELECTRONIC APPARATUS INCLUDING SAME | July 2021 | August 2025 | Allow | 50 | 2 | 1 | Yes | No |
| 17371847 | Methods for the Prevention and Treatment of Hearing Loss | July 2021 | September 2023 | Allow | 27 | 1 | 0 | No | No |
| 17348482 | POLYMORPHIC FORMS OF KINASE INHIBITOR COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, PREPARATION METHOD THEREFOR AND USE THEREOF | June 2021 | September 2024 | Allow | 39 | 2 | 1 | No | No |
| 17311314 | METHOD FOR PREPARING BORIC ACID ESTER USING UNCATALYZED HYDROBORATION OF CARBOXYLIC ACID | June 2021 | March 2025 | Abandon | 46 | 2 | 1 | No | No |
| 17333224 | SUSTAINED RELEASE DOSAGE FORMS FOR A JAK1 INHIBITOR | May 2021 | June 2024 | Allow | 37 | 1 | 1 | Yes | No |
| 17333266 | METHOD AGAINST CORONAVIRUS INFECTION WITH COUMARIN-DERIVED COMPOUND | May 2021 | December 2023 | Abandon | 31 | 2 | 0 | No | No |
| 17332394 | STABLE SILYLATING REAGENTS | May 2021 | March 2024 | Abandon | 33 | 1 | 1 | No | No |
| 17297271 | SOLID FORM, CRYSTALLINE FORM, AND CRYSTAL FORM A OF FXR AGONIST, AND PREPARATION METHOD AND APPLICATION THEREOF | May 2021 | September 2024 | Allow | 40 | 1 | 0 | Yes | No |
| 17327323 | IONIC TAGS FOR SYNTHESIS OF OLIGORIBONUCLEOTIDES | May 2021 | May 2024 | Abandon | 35 | 1 | 1 | No | No |
| 17324320 | TGF-ß INHIBITORS | May 2021 | September 2023 | Abandon | 28 | 1 | 1 | No | No |
| 17316823 | NOVEL COMPOUNDS USEFUL AS POTASSIUM CHANNEL OPENERS | May 2021 | October 2023 | Allow | 29 | 2 | 0 | No | No |
| 16971068 | NOVEL COMPOUND BASED ON VALEROLACTONE AND MEDICINE | May 2021 | July 2025 | Abandon | 59 | 2 | 1 | No | No |
| 17237453 | PHOTOSENSITIVE MATERIAL AND PHOTODETECTOR INCLUDING THE SAME | April 2021 | December 2024 | Allow | 43 | 1 | 3 | Yes | No |
| 17285967 | OXETANYLPHENOXYQUINOLINES AND ANALOGUES | April 2021 | July 2023 | Abandon | 26 | 0 | 1 | No | No |
| 17232764 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | April 2021 | February 2024 | Allow | 34 | 2 | 1 | Yes | No |
| 17229347 | AMIDE DERIVATIVES OF N-UREA SUBSTITUTED AMINO ACIDS AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS | April 2021 | October 2023 | Abandon | 30 | 2 | 0 | No | No |
| 17284434 | PROCESSES FOR PREPARING FUNCTIONALIZED CYCLOOCTENES | April 2021 | August 2024 | Allow | 40 | 0 | 1 | No | No |
| 17188710 | ANALOGS AND CONJUGATES OF BETA-AMINOISOBUTYRIC ACID (BAIB) | March 2021 | October 2024 | Allow | 43 | 1 | 1 | Yes | No |
| 17179509 | CYTOCHROME P450 INHIBITORS AND USES THEREOF | February 2021 | July 2023 | Abandon | 28 | 0 | 1 | No | No |
| 17180296 | SOLID STATE FORMS OF (S)-2-(((S)-6,8-DIFLUORO-1,2,3,4-TETRAHYDRONAPHTHALEN-2-YL)AMINO)-N-(1-(2-METHYL-1-(NEOPENTYLAMINO)PROPAN-2-YL)-1H-IMIDAZOL-4-YL)PENTANAMIDE AND USES THEREOF | February 2021 | October 2022 | Allow | 20 | 0 | 0 | Yes | No |
| 17172732 | SYSTEM AND METHOD FOR SOLUTION PHASE GAP PEPTIDE SYNTHESIS | February 2021 | March 2025 | Allow | 49 | 5 | 1 | Yes | No |
| 17166863 | METHODS FOR TREATING NEUROLOGICAL SYMPTOMS ASSOCIATED WITH LYSOSOMAL STORAGE DISEASES | February 2021 | May 2024 | Allow | 39 | 2 | 1 | Yes | No |
| 17263928 | PESTICIDAL COMPOSITIONS AND METHODS | January 2021 | December 2021 | Allow | 11 | 1 | 1 | Yes | No |
| 17152185 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | January 2021 | April 2023 | Abandon | 27 | 1 | 0 | Yes | No |
| 17256178 | ANIONIC DRUG-CONTAINING OPHTHALMIC DEVICE | December 2020 | September 2024 | Allow | 45 | 1 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner AGUIRRE, AMANDA L.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 20.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner AGUIRRE, AMANDA L works in Art Unit 1626 and has examined 749 patent applications in our dataset. With an allowance rate of 78.2%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 22 months.
Examiner AGUIRRE, AMANDA L's allowance rate of 78.2% places them in the 46% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by AGUIRRE, AMANDA L receive 1.27 office actions before reaching final disposition. This places the examiner in the 17% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by AGUIRRE, AMANDA L is 22 months. This places the examiner in the 88% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.
Conducting an examiner interview provides a +21.9% benefit to allowance rate for applications examined by AGUIRRE, AMANDA L. This interview benefit is in the 67% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 30.8% of applications are subsequently allowed. This success rate is in the 62% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 43.1% of cases where such amendments are filed. This entry rate is in the 66% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 80.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 62% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 91.7% of appeals filed. This is in the 84% percentile among all examiners. Of these withdrawals, 81.8% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 56.6% are granted (fully or in part). This grant rate is in the 59% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.1% of allowed cases (in the 50% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.7% of allowed cases (in the 72% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.